(Q34262817)

English

A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies (English)

1 reference

Europe PubMed Central

1 August 2017

author name string

Michael J Pishvaian

1

1 reference

Europe PubMed Central

1 August 2017

John L Marshall

2

1 reference

Europe PubMed Central

1 August 2017

Andrew J Wagner

3

1 reference

Europe PubMed Central

1 August 2017

Jimmy J Hwang

4

1 reference

Europe PubMed Central

1 August 2017

Shakun Malik

5

1 reference

Europe PubMed Central

1 August 2017

Ion Cotarla

6

1 reference

Europe PubMed Central

1 August 2017

John F Deeken

7

1 reference

Europe PubMed Central

1 August 2017

A Ruth He

8

1 reference

Europe PubMed Central

1 August 2017

Hirut Daniel

9

1 reference

Europe PubMed Central

1 August 2017

Abdel-Baset Halim

10

1 reference

Europe PubMed Central

1 August 2017

Hamim Zahir

11

1 reference

Europe PubMed Central

1 August 2017

Catherine Copigneaux

12

1 reference

Europe PubMed Central

1 August 2017

Kejian Liu

13

1 reference

Europe PubMed Central

1 August 2017

Robert A Beckman

14

1 reference

Europe PubMed Central

1 August 2017

George D Demetri

15

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

8 May 2012

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

118

1 reference

Europe PubMed Central

1 August 2017

21

1 reference

Europe PubMed Central

1 August 2017

5403-5413

1 reference

Europe PubMed Central

1 August 2017

Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

PPARgamma and MEK Interactions in Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-gamma Ligands in Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

The mechanisms of action of PPARs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Roles of PPARs in health and disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

6 July 2018

Early de novo gene expression is required for 15-deoxy-Delta 12,14-prostaglandin J2-induced apoptosis in breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27526

21 January 2018

Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27526

21 January 2018

Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27526

21 January 2018

Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor-gamma ligands

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27526

21 January 2018

Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27526

21 January 2018

Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726261

28 October 2018

Differentiation and reversal of malignant changes in colon cancer through PPARgamma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22570147

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction in Hematocrit and Hemoglobin Following Pioglitazone Treatment is not Hemodilutional in Type II Diabetes Mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/22570147

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22570147

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.27526

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34262817&oldid=1631602729"